Redhill Biopharma - ADR

NASDAQ:RDHL  
4.90
+0.08 (+1.66%)
Products, Regulatory, Other Pre-Announcement

Redhill Biopharma's Opaganib Shows Strong Inhibition Of COVID-19 Delta Variant

Published: 08/26/2021 10:56 GMT
Redhill Biopharma - ADR (RDHL) - Redhill Biopharma's Opaganib Demonstrates Strong Inhibition of Covid-19 Delta Variant.
Redhill Biopharma - Global 475-patient Phase 2/3 Study With Opaganib Oral Pill in Hospitalized Covid-19 Patients Completed Treatment, Follow Up Phase.
Redhill Biopharma - Opaganib Demonstrated Strong Inhibition of Covid-19 Delta Variant in a Human Bronchial Epithelial Cells Model.
Redhill Biopharma - Opaganib's Global 475-patient Phase 2/3 Study in Hospitalized Patients With Covid-19 Study Top-line Results Are Upcoming.